Efficacy and safety of KL-A167 in previously treated recurrent or metastatic nasopharyngeal carcinoma: a multicenter, single-arm, phase 2 study

BACKGROUND: KL-A167 is a fully humanized monoclonal antibody targeting programmed cell death-ligand 1. This phase 2 study aimed to evaluate the efficacy and safety of KL-A167 in Chinese patients with previously treated recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC). METHODS: This was a...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Yuankai, Qin, Xintian, Peng, Xingchen, Zeng, Aiping, Li, Jingao, Chen, Chuanben, Qiu, Sufang, Pan, Suming, Zheng, Yulong, Cai, Jing, Chen, Xiaopin, Qu, Shenhong, Lin, Lizhu, Huang, Jianli, Wu, Hui, Lu, Ying, Wang, Wei, Hu, Changlu, He, Xia, Yu, Zhonghua, Liu, Xiaojian, Xie, Bo, Liu, Anwen, Hu, Guangyuan, Jing, Shanghua, Zhang, Qingyuan, Guo, Renhua, Li, Qi, Hong, Jinsheng, Jin, Feng, Meng, Juan, Shi, Jianhua, Wang, Peiguo, Cui, Jiuwei, Yang, Kunyu, Zhang, Xuebang, Li, Xiaojiang, Shen, Liangfang, He, Yuxiang, Zhai, Limin, Sun, Xiuhua, Ge, Junyou, Qing, Yan, Zong, Dekang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9985015/
https://www.ncbi.nlm.nih.gov/pubmed/36879786
http://dx.doi.org/10.1016/j.lanwpc.2022.100617

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9985015/
https://www.ncbi.nlm.nih.gov/pubmed/36879786
http://dx.doi.org/10.1016/j.lanwpc.2022.100617

Ejemplares similares